Skip to content

Study · Not a test of the peptide alone · 1991

3 results

Interaction between thymic hormones and other immunomodulatory agents.

Mastino A, Favalli C, Grelli S, Garaci E

Annali dell'Istituto superiore di sanita1 Jan 1991

PMID1958028 (opens in a new tab)PepBankPUB-01958028
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In B-16 melanoma-bearing mice, combination treatment with thymosin alpha‑1 for 4 days followed by interferon restored normal NK cell activity.

    In plain wordsIn mice with melanoma, thymosin alpha‑1 followed by interferon restored normal NK cell activity.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNK cell activity
    Study

    mousen: not reported in source

    B-16 melanoma-bearing mice
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    However, combination treatment with TA1 (200 micrograms/kg) for 4 days, followed by IFN was found to restore normal NK cell activity.
    1 context sentence
    Summary · context
    We have investigated the effects of a combination in vivo treatment with thymosin alpha 1 (TA1) and murine alpha/beta interferon (IFN) on natural killer (NK) activity and on tumor growth in B-16 melanoma tumor-bearing mice.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In B-16 melanoma-bearing mice, primary tumor growth was unaffected by combination therapy with thymosin alpha‑1 and interferon.

    In plain wordsIn mice with melanoma, thymosin alpha‑1 plus interferon did not change primary tumor growth.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changePrimary tumor growth
    Study

    mousen: not reported in source

    B-16 melanoma-bearing mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    primary tumor growth was unaffected by combination therapy
    1 context sentence
    Summary · context
    We have investigated the effects of a combination in vivo treatment with thymosin alpha 1 (TA1) and murine alpha/beta interferon (IFN) on natural killer (NK) activity and on tumor growth in B-16 melanoma tumor-bearing mice.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In B-16 melanoma-bearing mice, thymosin alpha‑1 with interferon, started on day 6 after tumor inoculation, significantly prolonged survival time.

    In plain wordsIn mice with melanoma, thymosin alpha‑1 plus interferon lengthened survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time
    Study

    mousen: not reported in source

    B-16 melanoma-bearing mice
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    the same treatment with TA1 and IFN was able to significantly prolong survival time of B-16 tumor-bearing mice, when administered starting on day 6 after tumor inoculation.
    1 context sentence
    Summary · context
    We have investigated the effects of a combination in vivo treatment with thymosin alpha 1 (TA1) and murine alpha/beta interferon (IFN) on natural killer (NK) activity and on tumor growth in B-16 melanoma tumor-bearing mice.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.